CB
caVos develops mRNA therapies by identifying genetic variants conserved across long-lived species using evolutionary data and artificial intelligence. This approach generates a nature-validated atlas of therapeutic genetic variants prioritized for efficacy and safety in longevity applications. The company initially focuses on developing multi-target mRNA therapies for fibrosis and oncology based on these evolution-derived candidates.
Updated 3 months ago
Funding
$3.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- caVos develops mRNA therapies by identifying genetic variants conserved across long-lived species using evolutionary data and artificial intelligence. This approach generates a nature-validated atlas of therapeutic genetic variants prioritized for efficacy and safety in longevity applications. The company initially focuses on developing multi-target mRNA therapies for fibrosis and oncology based on these evolution-derived candidates.